ImmunoGuide® Enzyme immunoassay (ELISA) for the determination of free Certolizumab pegol (Cimzia®) in serum and plasma.
The drug Certolizumab pegol (trade name Cimzia®) is a tumor necrosis factor alpha (TNF-α) blocker and binds to human TNF-α with a KD of 90pM. Certolizumab pegol is a recombinant, humanized antibody Fab' fragment, with specificity for TNF-α, conjugated to an approximately 40kDa polyethylene glycol (PEG2MAL40K). The Fab' fragment is manufactured in E. coli and is subsequently subjected to purification and conjugation to PEG2MAL40K, to generate Certolizumab pegol.
The ImmunoGuide Certolizumab pegol ELISA (mAb-based) kit can be efficiently used for measuring free Certolizumab pegol levels in serum and plasma. For research use only, not for use in diagnostic procedures.
- Assay Description:
- 1 hour incubation (RT) + 1 hour (RT) + 30 min. (RT) + 10 min. (RT) = 2 hours, 40 min. total incubation time
- Catalog number:
- TM09023
- configuration:
- 96 Determinations, 12x8 removable strips
- controls:
- None provided
- design:
- Enzyme immunoassay (ELISA) technique
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- Available upon request
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Other names:
- Cimzia®
- Protocol:
- Sample types:
- Serum and plasma
- Sample volume:
- 10 µL
- standards:
- 5 standards, concentrated - require dilution prior to use
- Standard range:
- 0 / 6 -200 ng/mL
- storage:
- 2 - 8 °C
- sensitivity:
- 2 ng/mL
- Species:
- Human
- Products related:
- Additional info:
